

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Louis Panaccio
Date of last notice	30 December 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	12 December 2022 (United States) / 13 December 2022 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	70,460 CHESS Depository Interests in the Company quoted on the ASX ("CDIs") (representing beneficial ownership in 14,092 shares of common stock), of which Mr Panaccio is the registered holder. 29,860 CDIs (representing beneficial ownership in 5,927 shares of common stock), of which Tercus Pty Ltd atf The Panaccio Superannuation Fund is the registered holder. Mr Panaccio is one of two directors (along with his spouse), and one of two 50% shareholders (along with his spouse), of Tercus Pty Ltd (atf The Panaccio Superannuation Fund), as well as a beneficiary of The Panaccio Superannuation Fund. Mr Panaccio's relevant interest arises by virtue of sections 608(1)(b) and (c) of the <i>Corporations Act 2001</i> (Cth). 4,350 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs"), of which Mr Panaccio is the registered holder. 2,550 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18, of which Mr Panaccio is the registered holder.
Class	a) RSUs b) Options
Number acquired	a) 12,589 RSUs b) 5,395 Options expiring 13 Dec 2032 ex USD \$6.95
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	a) 70,460 CDIs b) 16,939 RSUs c) 2,550 options expiring 23 Dec 2031 ex USD \$12.18; and d) 5,395 options expiring 13 Dec 2032 ex USD \$6.95, of which Mr Panaccio is the registered holder. 29,860 CDIs of which Tercus Pty Ltd ATF The Panaccio Superannuation Fund is the registered holder (as noted above).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued in accordance with shareholder approval at the 2022 Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.